Protein Engineering vol. 9 no. 3 pp. 299-305, 1996
© 1996 Oxford University Press
RESEARCH-ARTICLE |
Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody
1MRC Centre for Protein Engineering Hills Road, Cambridge CB2 2QH, UK 3Department of Physiology, Vrije Universiteit 1090 Brussels, Belgium 4Blood Transfusion Service Long Road, Cambridge CB2 2PT, UK 55MRC Laboratory of Molecular Biology Hills Road, Cambridge CB2 2QH, UK
2To whom correspondence should be addressed
Antibody fragments produced by bacterial fermentation lack natural effector functions. Bispecific antibody fragments, however, can be endowed with effector functions, for example cell-mediated killing, by binding to and retargeting of cytotoxic cells. Diabodies are a class of engineered antibody fragments with two antigen binding sites, consisting of two associated chains; each chain consists of heavy and light chain variable domains linked by a short polypeptide linker. In contrast to IgG, or other antibody fragments in which the two binding sites can take up a range of orientations and spacings, the diabody structure is more rigid and compact, with the two binding sites separated by 65 Å (less than half the distance in IgG). To establish whether diabodies could also be used in cellmediated killing, we have explored the use of a bispecific diabody binding to an idiotypic marker on mouse B-cell lymphoma (BCL-1) and to mouse CD3. The bispecific diabody activated naive T-cells and also mediated the specific killing of the lymphoma cells by cytotoxic T-cells. The diabody was less active in T-cell activation but 10-fold more active (w/v) in killing than an analogous bispecific IgG.
Keywords: antibody fragments/bispecific antibody fragments/cytotoxicity/diabody/lymphoma
Received September 19, 1995; revised January 11, 1996; accepted January 18, 1996.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F. Le Gall, U. Reusch, M. Little, and S. M. Kipriyanov Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody Protein Eng. Des. Sel., April 1, 2004; 17(4): 357 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Kipriyanov, B. Cochlovius, H. J. Schafer, G. Moldenhauer, A. Bahre, F. Le Gall, S. Knackmuss, and M. Little Synergistic Antitumor Effect of Bispecific CD19 x CD3 and CD19 x CD16 Diabodies in a Preclinical Model of Non-Hodgkin's Lymphoma J. Immunol., July 1, 2002; 169(1): 137 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. K. Bera, J. Williams-Gould, R. Beers, P. Chowdhury, and I. Pastan Bivalent Disulfide-stabilized Fragment Variable Immunotoxin Directed against Mesotheliomas and Ovarian Cancer Mol. Cancer Ther., December 1, 2001; 1(2): 79 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Volkel, T. Korn, M. Bach, R. Muller, and R. E. Kontermann Optimized linker sequences for the expression of monomeric and dimeric bispecific single-chain diabodies Protein Eng. Des. Sel., October 1, 2001; 14(10): 815 - 823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Schmiedl, F. Breitling, and S. Dubel Expression of a bispecific dsFv-dsFv' antibody fragment in Escherichia coli Protein Eng. Des. Sel., October 1, 2000; 13(10): 725 - 734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Dolezal, L. A. Pearce, L. J. Lawrence, A. J. McCoy, P. J. Hudson, and A. A. Kortt ScFv multimers of the anti-neuraminidase antibody NC10: shortening of the linker in single-chain Fv fragment assembled in VL to VH orientation drives the formation of dimers, trimers, tetramers and higher molecular mass multimers Protein Eng. Des. Sel., August 1, 2000; 13(8): 565 - 574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-i. Takemura, R. Asano, K. Tsumoto, S. Ebara, N. Sakurai, Y. Katayose, H. Kodama, H. Yoshida, M. Suzuki, K. Imai, et al. Construction of a diabody (small recombinant bispecific antibody) using a refolding system Protein Eng. Des. Sel., August 1, 2000; 13(8): 583 - 588. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Cochlovius, S. M. Kipriyanov, M. J. J. G. Stassar, J. Schuhmacher, A. Benner, G. Moldenhauer, and M. Little Cure of Burkitt's Lymphoma in Severe Combined Immunodeficiency Mice by T Cells, Tetravalent CD3 CD19 Tandem Diabody, and CD28 Costimulation Cancer Res., August 1, 2000; 60(16): 4336 - 4341. [Abstract] [Full Text]
|
|
|
|
|
|
B. Cochlovius, S. M. Kipriyanov, M. J. J. G. Stassar, O. Christ, J. Schuhmacher, G. Strau{beta}, G. Moldenhauer, and M. Little Treatment of Human B Cell Lymphoma Xenografts with a CD3 CD19 Diabody and T Cells J. Immunol., July 15, 2000; 165(2): 888 - 895. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A.E. Arndt, J. Krauss, S. M. Kipriyanov, M. Pfreundschuh, and M. Little A Bispecific Diabody That Mediates Natural Killer Cell Cytotoxicity Against Xenotransplantated Human Hodgkin's Tumors Blood, October 15, 1999; 94(8): 2562 - 2568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Atwell, K. A. Breheney, L. J. Lawrence, A. J. McCoy, A. A. Kortt, and P. J. Hudson scFv multimers of the anti-neuraminidase antibody NC10: length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies Protein Eng. Des. Sel., July 1, 1999; 12(7): 597 - 604. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Holliger, O. Manzke, M. Span, R. Hawkins, B. Fleischmann, L. Qinghua, J. Wolf, V. Diehl, O. Cochet, G. Winter, et al. Carcinoembryonic Antigen (CEA)-specific T-Cell Activation in Colon Carcinoma Induced by Anti-CD3Anti-CEA Bispecific Diabodies and B7Anti-CEA Bispecific Fusion Proteins Cancer Res., June 1, 1999; 59(12): 2909 - 2916. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. De Jonge, C. Heirman, M. d. Veerman, S. Van Meirvenne, M. Moser, O. Leo, and K. Thielemans In Vivo Retargeting of T Cell Effector Function by Recombinant Bispecific Single Chain Fv (Anti-CD3 Anti-Idiotype) Induces Long-Term Survival in the Murine BCL1 Lymphoma Model J. Immunol., August 1, 1998; 161(3): 1454 - 1461. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Krebs, H. Griffin, G. Winter, and S. Rose-John Recombinant Human Single Chain Fv Antibodies Recognizing Human Interleukin-6. SPECIFIC TARGETING OF CYTOKINE-SECRETING CELLS J. Biol. Chem., January 30, 1998; 273(5): 2858 - 2865. [Abstract] [Full Text] [PDF]
|
|